_id
69185e853c536f8df2317d9c
Ticker
0R1B.LSE
Name
Biogen Inc.
Exchange
LSE
Address
225 Binney Street, Cambridge, MA, United States, 02142
Country
UK
Sector
Industry
Currency
USD
Website
https://www.biogen.com
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Last Close
176.84
Volume
469
Current Price
172.56
Change
-0.19226419362135455
Last Updated
2025-12-29T14:42:35.576Z
Image
https://logo.clearbit.com/www.biogen.com
Ipo Date
-
Market Cap
32541140000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
2454800000
Cost Of Revenue
876600000
Gross Profit
1578200000
Operating Expenses
964400000
Operating Income
613800000
Interest Expense
67400000
Pretax Income
557300000
Net Income
466500000
Eps
3.1713120326308633
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
90800000
EBITDA
826900000
Operating Margin
25.00407365162131
Total Other Income Expense Net
-56500000
Cash
3862800000
Short Term Investments
97600000
Receivables
1850000000
Inventories
2209400000
Total Current Assets
8936600000
Property Plant Equipment
3406200000
Total Assets
29207500000
Payables
413100000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
11000000000
Equity
18207500000
Bs_currency_symbol
-
Depreciation
202200000
Change In Working Capital
174200000
Cash From Operations
1272500000
Capital Expenditures
46200000
Cash From Investing
-35100000
Cash From Financing
-130199999
Net Change In Cash
1104000000
Cf_currency_symbol
-
PE
-
PB
1.394127474941645
ROE
2.562130989976658
ROA
1.5971925019258753
FCF
1226300000
Fcf Percent
0.49955189832165553
Piotroski FScore
4
Health Score
69
Deep Value Investing Score
8.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
8.3
Garp Investing Score
3.5
Growth Investing Score
3
Momentum Investing Score
4.5
Net Net Investing Score
4
Quality Investing Score
7
Value Investing Score
8.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
2454800000
Quarters > 0 > income Statement > cost Of Revenue
876600000
Quarters > 0 > income Statement > gross Profit
1578200000
Quarters > 0 > income Statement > operating Expenses
964400000
Quarters > 0 > income Statement > operating Income
613800000
Quarters > 0 > income Statement > interest Expense
67400000
Quarters > 0 > income Statement > pretax Income
557300000
Quarters > 0 > income Statement > net Income
466500000
Quarters > 0 > income Statement > eps
3.1713120326308633
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
147100000
Quarters > 0 > income Statement > income Tax Expense
90800000
Quarters > 0 > income Statement > EBITDA
826900000
Quarters > 0 > income Statement > operating Margin
25.00407365162131
Quarters > 0 > income Statement > total Other Income Expense Net
-56500000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
3862800000
Quarters > 0 > balance Sheet > short Term Investments
97600000
Quarters > 0 > balance Sheet > receivables
1850000000
Quarters > 0 > balance Sheet > inventories
2209400000
Quarters > 0 > balance Sheet > total Current Assets
8936600000
Quarters > 0 > balance Sheet > property Plant Equipment
3406200000
Quarters > 0 > balance Sheet > total Assets
29207500000
Quarters > 0 > balance Sheet > payables
413100000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
11000000000
Quarters > 0 > balance Sheet > equity
18207500000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
466500000
Quarters > 0 > cash Flow > depreciation
202200000
Quarters > 0 > cash Flow > change In Working Capital
174200000
Quarters > 0 > cash Flow > cash From Operations
1272500000
Quarters > 0 > cash Flow > capital Expenditures
46200000
Quarters > 0 > cash Flow > cash From Investing
-35100000
Quarters > 0 > cash Flow > cash From Financing
-130199999
Quarters > 0 > cash Flow > net Change In Cash
1104000000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
3.1713120326308633
Quarters > 0 > ratios > PB
1.394127474941645
Quarters > 0 > ratios > ROE
2.562130989976658
Quarters > 0 > ratios > ROA
1.5971925019258753
Quarters > 0 > ratios > FCF
1226300000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.49955189832165553
Quarters > 0 > health Score
69
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
2645500000
Quarters > 1 > income Statement > cost Of Revenue
946200000
Quarters > 1 > income Statement > gross Profit
1699300000
Quarters > 1 > income Statement > operating Expenses
1111200000
Quarters > 1 > income Statement > operating Income
588100000
Quarters > 1 > income Statement > interest Expense
72600000
Quarters > 1 > income Statement > pretax Income
744000000
Quarters > 1 > income Statement > net Income
634800000
Quarters > 1 > income Statement > eps
4.3509252912954075
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
145900000
Quarters > 1 > income Statement > income Tax Expense
109200000
Quarters > 1 > income Statement > EBITDA
1109900000
Quarters > 1 > income Statement > operating Margin
22.23020223020223
Quarters > 1 > income Statement > total Other Income Expense Net
155900000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
2758800000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
2084000000
Quarters > 1 > balance Sheet > inventories
2274300000
Quarters > 1 > balance Sheet > total Current Assets
7967700000
Quarters > 1 > balance Sheet > property Plant Equipment
3433300000
Quarters > 1 > balance Sheet > total Assets
28330200000
Quarters > 1 > balance Sheet > payables
408400000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
10696200000
Quarters > 1 > balance Sheet > equity
17634000000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
634800000
Quarters > 1 > cash Flow > depreciation
194300000
Quarters > 1 > cash Flow > change In Working Capital
-789600000
Quarters > 1 > cash Flow > cash From Operations
160900000
Quarters > 1 > cash Flow > capital Expenditures
16600000
Quarters > 1 > cash Flow > cash From Investing
-57000000
Quarters > 1 > cash Flow > cash From Financing
-11700000
Quarters > 1 > cash Flow > net Change In Cash
160500000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
4.3509252912954075
Quarters > 1 > ratios > PB
1.427725076556652
Quarters > 1 > ratios > ROE
3.5998638992854715
Quarters > 1 > ratios > ROA
2.2407183853273187
Quarters > 1 > ratios > FCF
144300000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.05454545454545454
Quarters > 1 > health Score
55
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
2431000000
Quarters > 2 > income Statement > cost Of Revenue
577900000
Quarters > 2 > income Statement > gross Profit
1853100000
Quarters > 2 > income Statement > operating Expenses
1120500000
Quarters > 2 > income Statement > operating Income
732600000
Quarters > 2 > income Statement > interest Expense
60000000
Quarters > 2 > income Statement > pretax Income
311200000
Quarters > 2 > income Statement > net Income
240500000
Quarters > 2 > income Statement > eps
1.648389307745031
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
145900000
Quarters > 2 > income Statement > income Tax Expense
70700000
Quarters > 2 > income Statement > EBITDA
865100000
Quarters > 2 > income Statement > operating Margin
30.13574660633484
Quarters > 2 > income Statement > total Other Income Expense Net
-421400000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
2598300000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1996500000
Quarters > 2 > balance Sheet > inventories
2273900000
Quarters > 2 > balance Sheet > total Current Assets
7626000000
Quarters > 2 > balance Sheet > property Plant Equipment
3478800000
Quarters > 2 > balance Sheet > total Assets
28033100000
Quarters > 2 > balance Sheet > payables
391500000
Quarters > 2 > balance Sheet > short Term Debt
1749100000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
11054400000
Quarters > 2 > balance Sheet > equity
16978700000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
240500000
Quarters > 2 > cash Flow > depreciation
183200000
Quarters > 2 > cash Flow > change In Working Capital
-333500000
Quarters > 2 > cash Flow > cash From Operations
259300000
Quarters > 2 > cash Flow > capital Expenditures
47100000
Quarters > 2 > cash Flow > cash From Investing
-47300000
Quarters > 2 > cash Flow > cash From Financing
-23000000
Quarters > 2 > cash Flow > net Change In Cash
223300000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
1.648389307745031
Quarters > 2 > ratios > PB
1.482828720691219
Quarters > 2 > ratios > ROE
1.416480649284103
Quarters > 2 > ratios > ROA
0.8579143940555987
Quarters > 2 > ratios > FCF
212200000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.08728918140682847
Quarters > 2 > health Score
56
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
2454700000
Quarters > 3 > income Statement > cost Of Revenue
583500000
Quarters > 3 > income Statement > gross Profit
1871200000
Quarters > 3 > income Statement > operating Expenses
1362200000
Quarters > 3 > income Statement > operating Income
509000000
Quarters > 3 > income Statement > interest Expense
60000000
Quarters > 3 > income Statement > pretax Income
291500000
Quarters > 3 > income Statement > net Income
266700000
Quarters > 3 > income Statement > eps
1.8254620123203285
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
146100000
Quarters > 3 > income Statement > income Tax Expense
24800000
Quarters > 3 > income Statement > EBITDA
691700000
Quarters > 3 > income Statement > operating Margin
20.73573145394549
Quarters > 3 > income Statement > total Other Income Expense Net
-217500000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
2375000000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1868800000
Quarters > 3 > balance Sheet > inventories
2460500000
Quarters > 3 > balance Sheet > total Current Assets
7456800000
Quarters > 3 > balance Sheet > property Plant Equipment
3537700000
Quarters > 3 > balance Sheet > total Assets
28049300000
Quarters > 3 > balance Sheet > payables
424200000
Quarters > 3 > balance Sheet > short Term Debt
1748600000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
11333300000
Quarters > 3 > balance Sheet > equity
16716000000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
266700000
Quarters > 3 > cash Flow > depreciation
184000000
Quarters > 3 > cash Flow > change In Working Capital
28300000
Quarters > 3 > cash Flow > cash From Operations
760900000
Quarters > 3 > cash Flow > capital Expenditures
66300000
Quarters > 3 > cash Flow > cash From Investing
-18600000
Quarters > 3 > cash Flow > cash From Financing
7900000
Quarters > 3 > cash Flow > net Change In Cash
675800000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
1.8254620123203285
Quarters > 3 > ratios > PB
1.508196697774587
Quarters > 3 > ratios > ROE
1.5954773869346732
Quarters > 3 > ratios > ROA
0.9508258673121969
Quarters > 3 > ratios > FCF
694600000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.2829673687212287
Quarters > 3 > health Score
68
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
9675900000
Annuals > 0 > income Statement > cost Of Revenue
2310400000
Annuals > 0 > income Statement > gross Profit
7365500000
Annuals > 0 > income Statement > operating Expenses
4875200000
Annuals > 0 > income Statement > operating Income
2490300000
Annuals > 0 > income Statement > interest Expense
250300000
Annuals > 0 > income Statement > pretax Income
1906000000
Annuals > 0 > income Statement > net Income
1632200000
Annuals > 0 > income Statement > eps
11.187114461960247
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
145900000
Annuals > 0 > income Statement > income Tax Expense
273800000
Annuals > 0 > income Statement > EBITDA
2995700000
Annuals > 0 > income Statement > operating Margin
25.737140731094783
Annuals > 0 > income Statement > total Other Income Expense Net
-584300000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
2375000000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
1868800000
Annuals > 0 > balance Sheet > inventories
2460500000
Annuals > 0 > balance Sheet > total Current Assets
7456800000
Annuals > 0 > balance Sheet > property Plant Equipment
3537700000
Annuals > 0 > balance Sheet > total Assets
28049300000
Annuals > 0 > balance Sheet > payables
424200000
Annuals > 0 > balance Sheet > short Term Debt
1748600000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
11333300000
Annuals > 0 > balance Sheet > equity
16716000000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
1632200000
Annuals > 0 > cash Flow > depreciation
673200000
Annuals > 0 > cash Flow > change In Working Capital
-155200000
Annuals > 0 > cash Flow > cash From Operations
2875500000
Annuals > 0 > cash Flow > capital Expenditures
359800000
Annuals > 0 > cash Flow > cash From Investing
-799200000
Annuals > 0 > cash Flow > cash From Financing
-683500000
Annuals > 0 > cash Flow > net Change In Cash
1325100000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
11.187114461960247
Annuals > 0 > ratios > PB
1.5427903804737975
Annuals > 0 > ratios > ROE
9.764297678870543
Annuals > 0 > ratios > ROA
5.81904004734521
Annuals > 0 > ratios > FCF
2515700000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.2599964861149867
Annuals > 0 > health Score
76
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
9835600000
Annuals > 1 > income Statement > cost Of Revenue
2533400000
Annuals > 1 > income Statement > gross Profit
7302200000
Annuals > 1 > income Statement > operating Expenses
5204900000
Annuals > 1 > income Statement > operating Income
2097300000
Annuals > 1 > income Statement > interest Expense
246900000
Annuals > 1 > income Statement > pretax Income
1296800000
Annuals > 1 > income Statement > net Income
1161100000
Annuals > 1 > income Statement > eps
7.974587912087912
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
145600000
Annuals > 1 > income Statement > income Tax Expense
135300000
Annuals > 1 > income Statement > EBITDA
2377000000
Annuals > 1 > income Statement > operating Margin
21.323559315140916
Annuals > 1 > income Statement > total Other Income Expense Net
-800500000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
1049900000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
2100000000
Annuals > 1 > balance Sheet > inventories
2527400000
Annuals > 1 > balance Sheet > total Current Assets
6859300000
Annuals > 1 > balance Sheet > property Plant Equipment
3729700000
Annuals > 1 > balance Sheet > total Assets
26844800000
Annuals > 1 > balance Sheet > payables
403300000
Annuals > 1 > balance Sheet > short Term Debt
150000000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
12045400000
Annuals > 1 > balance Sheet > equity
14799400000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
1161500000
Annuals > 1 > cash Flow > depreciation
494800000
Annuals > 1 > cash Flow > change In Working Capital
-648700000
Annuals > 1 > cash Flow > cash From Operations
1547200000
Annuals > 1 > cash Flow > capital Expenditures
311400000
Annuals > 1 > cash Flow > cash From Investing
-4088700000
Annuals > 1 > cash Flow > cash From Financing
137000000
Annuals > 1 > cash Flow > net Change In Cash
-2369400000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
7.974587912087912
Annuals > 1 > ratios > PB
1.7390067164885061
Annuals > 1 > ratios > ROE
7.845588334662216
Annuals > 1 > ratios > ROA
4.325232447252354
Annuals > 1 > ratios > FCF
1235800000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.1256456138923909
Annuals > 1 > health Score
68
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
10173400000
Annuals > 2 > income Statement > cost Of Revenue
2278300000
Annuals > 2 > income Statement > gross Profit
7895100000
Annuals > 2 > income Statement > operating Expenses
5006000000
Annuals > 2 > income Statement > operating Income
2889100000
Annuals > 2 > income Statement > interest Expense
246600000
Annuals > 2 > income Statement > pretax Income
3594400000
Annuals > 2 > income Statement > net Income
3046900000
Annuals > 2 > income Statement > eps
20.86917808219178
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
146000000
Annuals > 2 > income Statement > income Tax Expense
632800000
Annuals > 2 > income Statement > EBITDA
3536900000
Annuals > 2 > income Statement > operating Margin
28.398568816718107
Annuals > 2 > income Statement > total Other Income Expense Net
705300000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
3419300000
Annuals > 2 > balance Sheet > short Term Investments
1473500000
Annuals > 2 > balance Sheet > receivables
2136400000
Annuals > 2 > balance Sheet > inventories
1344400000
Annuals > 2 > balance Sheet > total Current Assets
9791200000
Annuals > 2 > balance Sheet > property Plant Equipment
3702500000
Annuals > 2 > balance Sheet > total Assets
24554100000
Annuals > 2 > balance Sheet > payables
491500000
Annuals > 2 > balance Sheet > short Term Debt
194400000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
11165700000
Annuals > 2 > balance Sheet > equity
13397900000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
2961600000
Annuals > 2 > cash Flow > depreciation
518400000
Annuals > 2 > cash Flow > change In Working Capital
-890300000
Annuals > 2 > cash Flow > cash From Operations
1384300000
Annuals > 2 > cash Flow > capital Expenditures
240300000
Annuals > 2 > cash Flow > cash From Investing
1589000000
Annuals > 2 > cash Flow > cash From Financing
-1759700000
Annuals > 2 > cash Flow > net Change In Cash
1157900000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
20.86917808219178
Annuals > 2 > ratios > PB
1.926194403600564
Annuals > 2 > ratios > ROE
22.741623687294275
Annuals > 2 > ratios > ROA
12.40892559694715
Annuals > 2 > ratios > FCF
1144000000
Annuals > 2 > ratios > Piotroski FScore
3
Annuals > 2 > ratios > fcf Percent
0.11245011500579943
Annuals > 2 > health Score
78
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
10981700000
Annuals > 3 > income Statement > cost Of Revenue
2109699999
Annuals > 3 > income Statement > gross Profit
8872000000
Annuals > 3 > income Statement > operating Expenses
6080600000
Annuals > 3 > income Statement > operating Income
2791400000
Annuals > 3 > income Statement > interest Expense
253600000
Annuals > 3 > income Statement > pretax Income
1780100000
Annuals > 3 > income Statement > net Income
1556100000
Annuals > 3 > income Statement > eps
10.401737967914439
Annuals > 3 > income Statement > dividends Per Share
1
Annuals > 3 > income Statement > shares Outstanding
149600000
Annuals > 3 > income Statement > income Tax Expense
52500000
Annuals > 3 > income Statement > EBITDA
3923400000
Annuals > 3 > income Statement > operating Margin
25.418651028529283
Annuals > 3 > income Statement > total Other Income Expense Net
-1011300000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
2261400000
Annuals > 3 > balance Sheet > short Term Investments
1541100000
Annuals > 3 > balance Sheet > receivables
1961700000
Annuals > 3 > balance Sheet > inventories
1351500000
Annuals > 3 > balance Sheet > total Current Assets
7856500000
Annuals > 3 > balance Sheet > property Plant Equipment
3791800000
Annuals > 3 > balance Sheet > total Assets
23877300000
Annuals > 3 > balance Sheet > payables
589200000
Annuals > 3 > balance Sheet > short Term Debt
999100000
Annuals > 3 > balance Sheet > long Term Debt
6274000000
Annuals > 3 > balance Sheet > total Liabilities
12917600000
Annuals > 3 > balance Sheet > equity
10896200000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
1727600000
Annuals > 3 > cash Flow > depreciation
487700000
Annuals > 3 > cash Flow > change In Working Capital
-145500000
Annuals > 3 > cash Flow > cash From Operations
3639900000
Annuals > 3 > cash Flow > capital Expenditures
258100000
Annuals > 3 > cash Flow > cash From Investing
-563700000
Annuals > 3 > cash Flow > cash From Financing
-2086199999
Annuals > 3 > cash Flow > net Change In Cash
930200000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
10.401737967914439
Annuals > 3 > ratios > PB
2.4268365118114574
Annuals > 3 > ratios > ROE
14.281125530001285
Annuals > 3 > ratios > ROA
6.517068512771544
Annuals > 3 > ratios > FCF
3381800000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.3079486782556435
Annuals > 3 > health Score
74
Valuation > metrics > PE
3.1713120326308633
Valuation > metrics > PB
1.394127474941645
Valuation > final Score
100
Valuation > verdict
34.1% Undervalued
Profitability > metrics > ROE
2.562130989976658
Profitability > metrics > ROA
5.220106080612314
Profitability > metrics > Net Margin
0.19003584813426755
Profitability > final Score
49
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6041466428669504
Risk > metrics > Interest Coverage
9.106824925816024
Risk > final Score
84
Risk > verdict
Low
Liquidity > metrics > Current Ratio
21.63301863955459
Liquidity > metrics > Quick Ratio
16.28467683369644
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
61
Prev Profitabilities > 1
27
Prev Profitabilities > 2
30
Prev Risks > 0
80
Prev Risks > 1
88
Prev Risks > 2
82
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:58:17.702Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-29
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-02-11
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
1.75
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-09-30
Earnings History > 2 > report Date
2025-10-30
Earnings History > 2 > date
2025-09-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
4.81
Earnings History > 2 > eps Estimate
3.88
Earnings History > 2 > eps Difference
0.93
Earnings History > 2 > surprise Percent
23.9691
Earnings History > 3 > period
2025-06-30
Earnings History > 3 > report Date
2025-07-31
Earnings History > 3 > date
2025-06-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
4.3272
Earnings History > 3 > eps Estimate
3.88
Earnings History > 3 > eps Difference
0.4472
Earnings History > 3 > surprise Percent
11.5258
Earnings History > 4 > period
2025-03-31
Earnings History > 4 > report Date
2025-05-01
Earnings History > 4 > date
2025-03-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
1.6405
Earnings History > 4 > eps Estimate
3.56
Earnings History > 4 > eps Difference
-1.9195
Earnings History > 4 > surprise Percent
-53.9185
Earnings History > 5 > period
2024-12-31
Earnings History > 5 > report Date
2025-02-12
Earnings History > 5 > date
2024-12-31
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
1.8261
Earnings History > 5 > eps Estimate
3.41
Earnings History > 5 > eps Difference
-1.5839
Earnings History > 5 > surprise Percent
-46.4487
Earnings History > 6 > period
2024-09-30
Earnings History > 6 > report Date
2024-10-30
Earnings History > 6 > date
2024-09-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
2.6591
Earnings History > 6 > eps Estimate
3.77
Earnings History > 6 > eps Difference
-1.1109
Earnings History > 6 > surprise Percent
-29.4668
Earnings History > 7 > period
2024-06-30
Earnings History > 7 > report Date
2024-08-01
Earnings History > 7 > date
2024-06-30
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
4
Earnings History > 7 > eps Estimate
4.07
Earnings History > 7 > eps Difference
-0.07
Earnings History > 7 > surprise Percent
-1.7199
Earnings History > 8 > period
2024-03-31
Earnings History > 8 > report Date
2024-04-24
Earnings History > 8 > date
2024-03-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
2.6964
Earnings History > 8 > eps Estimate
3.67
Earnings History > 8 > eps Difference
-0.9736
Earnings History > 8 > surprise Percent
-26.5286
Earnings History > 9 > period
2023-12-31
Earnings History > 9 > report Date
2024-02-13
Earnings History > 9 > date
2023-12-31
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
1.7138
Earnings History > 9 > eps Estimate
2.95
Earnings History > 9 > eps Difference
-1.2362
Earnings History > 9 > surprise Percent
-41.9051
Earnings History > 10 > period
2023-09-30
Earnings History > 10 > report Date
2023-11-08
Earnings History > 10 > date
2023-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
-
Earnings History > 10 > eps Actual
-0.4703
Earnings History > 10 > eps Estimate
4.36
Earnings History > 10 > eps Difference
-4.8303
Earnings History > 10 > surprise Percent
-110.7867
Earnings History > 11 > period
2023-06-30
Earnings History > 11 > report Date
2023-07-25
Earnings History > 11 > date
2023-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
-
Earnings History > 11 > eps Actual
4.066
Earnings History > 11 > eps Estimate
4.02
Earnings History > 11 > eps Difference
0.046
Earnings History > 11 > surprise Percent
1.1443
Earnings History > 12 > period
2023-03-31
Earnings History > 12 > report Date
2023-04-25
Earnings History > 12 > date
2023-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
2.6715
Earnings History > 12 > eps Estimate
3.4
Earnings History > 12 > eps Difference
-0.7285
Earnings History > 12 > surprise Percent
-21.4265
Earnings History > 13 > period
2022-12-31
Earnings History > 13 > report Date
2023-02-15
Earnings History > 13 > date
2022-12-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
-
Earnings History > 13 > eps Actual
3.7906
Earnings History > 13 > eps Estimate
4.05
Earnings History > 13 > eps Difference
-0.2594
Earnings History > 13 > surprise Percent
-6.4049
Earnings History > 14 > period
2022-09-30
Earnings History > 14 > report Date
2022-10-25
Earnings History > 14 > date
2022-09-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
-
Earnings History > 14 > eps Actual
7.8363
Earnings History > 14 > eps Estimate
4.77
Earnings History > 14 > eps Difference
3.0663
Earnings History > 14 > surprise Percent
64.283
Earnings History > 15 > period
2022-06-30
Earnings History > 15 > report Date
2022-07-20
Earnings History > 15 > date
2022-06-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
-
Earnings History > 15 > eps Actual
7.2367
Earnings History > 15 > eps Estimate
5.25
Earnings History > 15 > eps Difference
1.9867
Earnings History > 15 > surprise Percent
37.8419
Earnings History > 16 > period
2022-03-31
Earnings History > 16 > report Date
2022-05-03
Earnings History > 16 > date
2022-03-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
-
Earnings History > 16 > eps Actual
2.0583
Earnings History > 16 > eps Estimate
3.62
Earnings History > 16 > eps Difference
-1.5617
Earnings History > 16 > surprise Percent
-43.1409
Earnings History > 17 > period
2021-12-31
Earnings History > 17 > report Date
2022-02-03
Earnings History > 17 > date
2021-12-31
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
-
Earnings History > 17 > eps Actual
2.4963
Earnings History > 17 > eps Estimate
3.39
Earnings History > 17 > eps Difference
-0.8937
Earnings History > 17 > surprise Percent
-26.3628
Earnings History > 18 > period
2021-09-30
Earnings History > 18 > report Date
2021-10-20
Earnings History > 18 > date
2021-09-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
-
Earnings History > 18 > eps Actual
2.2153
Earnings History > 18 > eps Estimate
4.77
Earnings History > 18 > eps Difference
-2.5547
Earnings History > 18 > surprise Percent
-53.5577
Earnings History > 19 > period
2021-06-30
Earnings History > 19 > report Date
2021-07-22
Earnings History > 19 > date
2021-06-30
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
-
Earnings History > 19 > eps Actual
2.988
Earnings History > 19 > eps Estimate
5.68
Earnings History > 19 > eps Difference
-2.692
Earnings History > 19 > surprise Percent
-47.3944
Earnings History > 20 > period
2021-03-31
Earnings History > 20 > report Date
2021-04-22
Earnings History > 20 > date
2021-03-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
-
Earnings History > 20 > eps Actual
2.6934
Earnings History > 20 > eps Estimate
5.34
Earnings History > 20 > eps Difference
-2.6466
Earnings History > 20 > surprise Percent
-49.5618
Earnings History > 21 > period
2020-12-31
Earnings History > 21 > report Date
2021-02-03
Earnings History > 21 > date
2020-12-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
-
Earnings History > 21 > eps Actual
2.324
Earnings History > 21 > eps Estimate
4.58
Earnings History > 21 > eps Difference
-2.256
Earnings History > 21 > surprise Percent
-49.2576
Earnings History > 22 > period
2020-09-30
Earnings History > 22 > report Date
2020-10-21
Earnings History > 22 > date
2020-09-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
-
Earnings History > 22 > eps Actual
4.4625
Earnings History > 22 > eps Estimate
8.84
Earnings History > 22 > eps Difference
-4.3775
Earnings History > 22 > surprise Percent
-49.5192
Earnings History > 23 > period
2020-06-30
Earnings History > 23 > report Date
2020-07-22
Earnings History > 23 > date
2020-06-30
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
-
Earnings History > 23 > eps Actual
9.5842
Earnings History > 23 > eps Estimate
10.26
Earnings History > 23 > eps Difference
-0.6758
Earnings History > 23 > surprise Percent
-6.5867
Earnings History > 24 > period
2020-03-31
Earnings History > 24 > report Date
2020-04-22
Earnings History > 24 > date
2020-03-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
-
Earnings History > 24 > eps Actual
8.0826
Earnings History > 24 > eps Estimate
9.14
Earnings History > 24 > eps Difference
-1.0574
Earnings History > 24 > surprise Percent
-11.5689
Earnings History > 25 > period
2019-12-31
Earnings History > 25 > report Date
2020-01-30
Earnings History > 25 > date
2019-12-31
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
-
Earnings History > 25 > eps Actual
8.0791
Earnings History > 25 > eps Estimate
8.34
Earnings History > 25 > eps Difference
-0.2609
Earnings History > 25 > surprise Percent
-3.1283
Earnings History > 26 > period
2019-09-30
Earnings History > 26 > report Date
2019-10-22
Earnings History > 26 > date
2019-09-30
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
-
Earnings History > 26 > eps Actual
8.3925
Earnings History > 26 > eps Estimate
9.17
Earnings History > 26 > eps Difference
-0.7775
Earnings History > 26 > surprise Percent
-8.4787
Earnings History > 27 > period
2019-06-30
Earnings History > 27 > report Date
2019-07-23
Earnings History > 27 > date
2019-06-30
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
-
Earnings History > 27 > eps Actual
7.8472
Earnings History > 27 > eps Estimate
9.15
Earnings History > 27 > eps Difference
-1.3028
Earnings History > 27 > surprise Percent
-14.2383
Earnings History > 28 > period
2019-03-31
Earnings History > 28 > report Date
2019-03-31
Earnings History > 28 > date
2019-03-31
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
-
Earnings History > 28 > eps Actual
7.1513
Earnings History > 28 > eps Estimate
-
Earnings History > 28 > eps Difference
0
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2018-12-31
Earnings History > 29 > report Date
2018-12-31
Earnings History > 29 > date
2018-12-31
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
-
Earnings History > 29 > eps Actual
4.7269
Earnings History > 29 > eps Estimate
-
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2018-09-30
Earnings History > 30 > report Date
2018-09-30
Earnings History > 30 > date
2018-09-30
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
-
Earnings History > 30 > eps Actual
7.154
Earnings History > 30 > eps Estimate
-
Earnings History > 30 > eps Difference
0
Earnings History > 30 > surprise Percent
-
Earnings History > 31 > period
2018-06-30
Earnings History > 31 > report Date
2018-06-30
Earnings History > 31 > date
2018-06-30
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
-
Earnings History > 31 > eps Actual
4.1804
Earnings History > 31 > eps Estimate
-
Earnings History > 31 > eps Difference
0
Earnings History > 31 > surprise Percent
-
Earnings History > 32 > period
2018-03-31
Earnings History > 32 > report Date
2018-03-31
Earnings History > 32 > date
2018-03-31
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
-
Earnings History > 32 > eps Actual
5.5404
Earnings History > 32 > eps Estimate
-
Earnings History > 32 > eps Difference
0
Earnings History > 32 > surprise Percent
-
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Biogen Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
1.75
Date
2025-09-30
EPS Actual
4.81
EPS Estimate
3.88
EPS Difference
0.93
Surprise Percent
23.9691%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.